Immune Design (Immune Design) Insider Ownership : 1.36 % (As of May. 06, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Immune Design Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immune Design's insider ownership is 1.36%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immune Design's Institutional Ownership is 61.83%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immune Design's Float Percentage Of Total Shares Outstanding is 62.44%.

Immune Design Insider Ownership Historical Data

The historical data trend for Immune Design's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design Insider Ownership Chart

Immune Design Historical Data

The historical data trend for Immune Design can be seen below:

	2018-05-31	2018-06-30	2018-07-31	2018-08-31	2018-09-30	2018-10-31	2018-11-30	2018-12-31	2019-01-31	2019-02-28
Insider Ownership	0.95	0.95	0.95	0.95	0.95	0.95	1.13	1.36	1.36	1.36

Immune Design Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Immune Design (Immune Design) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102

Website

http://www.immunedesign.com

Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.

Executives

William R Ringo	director
David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet	director	ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya	director, officer: President and CEO	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005